The reduction impact of monoglucosyl rutin on abdominal visceral fat: a randomized, placebo-controlled, double-blind, parallel-group study
Hashizume Y, Tandia M
Published in Journal of Food Science
Methodology
Randomized, placebo-controlled, double-blind, parallel-group trial in 66 healthy Japanese adults with BMI 23-30 receiving monoglucosyl rutin 200 mg/day, 400 mg/day or placebo for eight weeks, with abdominal visceral fat area as the primary outcome
Key Findings
Both monoglucosyl rutin doses reduced abdominal visceral fat area versus placebo at eight weeks.
Conclusions
Applies to a water-soluble glycosylated rutin derivative, not standard rutin; industry-relevant and unreplicated.
Limitations
Small per-protocol sample; modified compound; eight weeks; likely manufacturer interest.
Supplements Studied
AVF area in both the MR200 and MR400 groups was reduced at week 8, with changes from the baseline (week 0) significantly higher than the placebo group.
Study Details
Access Study
Disclosures
Funding
Not reported
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.